Neuraxis (NRXS) Times Interest Earned (2022 - 2025)
Neuraxis (NRXS) posted Times Interest Earned of $51.28 for Q4 2025, up 172.43% sequentially from -$70.8 in Q3 2025, and up 382.9% YoY from $10.62 in Q4 2024.
Neuraxis (NRXS) Times Interest Earned (2022 - 2025) Analysis & Trends
Neuraxis has reported Times Interest Earned for 4 years, with the latest figure at $51.28 in Q4 2025.
- Quarterly Times Interest Earned rose 382.9% year-over-year to $51.28 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $101.36 (up 850.7% YoY) and the FY2025 annual result came in at -$21.68, down 75.79% from the prior year.
- Times Interest Earned improved to $51.28 in Q4 2025 per NRXS's latest filing, from -$70.8 in the prior quarter.
- Over five years, Times Interest Earned peaked at $51.28 in Q4 2025 and troughed at -$1205.1 in Q4 2023.
- A 4-year average of -$162.58 and a median of -$19.44 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2025: Times Interest Earned tumbled 4969.59% in 2023, then soared 382.9% in 2025.
- Over 4 years, Times Interest Earned stood at -$23.77 in 2022, then slumped by 4969.59% to -$1205.1 in 2023, then jumped by 100.88% to $10.62 in 2024, then jumped by 382.9% to $51.28 in 2025.
- According to Business Quant data, Times Interest Earned over the past three periods registered $51.28, -$70.8, and -$4.59 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.28 |
| Sep 30, 2025 | -70.80 |
| Jun 30, 2025 | -4.59 |
| Mar 31, 2025 | -1,025.97 |
| Dec 31, 2024 | 10.62 |
| Sep 30, 2024 | -25.53 |
| Jun 30, 2024 | -3.83 |
| Mar 31, 2024 | -68.98 |
| Dec 31, 2023 | -1,205.05 |
| Sep 30, 2023 | -29.45 |
| Jun 30, 2023 | -5.74 |
| Mar 31, 2023 | -5.54 |
| Dec 31, 2022 | -23.77 |
| Sep 30, 2022 | -11.94 |
| Jun 30, 2022 | -19.44 |